PCN182 Generating Health State Utility Values from Fact-Ovarian Data Collected in a Phase Ii Maintenance Study in Platinum Sensitive Recurrent Ovarian Cancer (Study 19): A Comparison of Mapping Algorithms  by Hettle, R. et al.
A646  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
algorithms mapping FACT-G to EuroQol (EQ-5D) [(Cheung, 2009), Ordinary Least 
Squares (OLS) and Tobit (Longworth, 2014)] and one from FACT-G to Time-Trade-
Off (Dobrez, 2007) were applied to data from the phase II study. The agreement 
between HSUVs was assessed using concordance correlation coefficients (CCCs), 
and paired t-tests for mean HSUVs. Results: HSUVs were generated for 93% of 
patients in the study. Mean predicted HSUVs using OLS and Tobit were statisti-
cally consistent (p-value= 0.947), whilst Cheung and Dobrez HSUVs were different 
from other algorithms (p-values < 0.05). The CCCs comparing OLS to Tobit and 
OLS to Cheung were 0.915 and 0.851, respectively. The CCCs comparing Dobrez 
to the EQ-5D algorithms were 0.629 (OLS), 0.619 (Tobit) and 0.783 (Cheung). The 
lowest and highest mean predicted HSUVs were estimated using OLS and Dobrez, 
respectively. ConClusions: HSUVs can be estimated from FACT-O using FACT-G 
mapping algorithms. Comparable HSUVs were generated using OLS and Tobit algo-
rithms, whilst Cheung and Dobrez generated distinct HSUVs profiles. Without trial 
data directly comparing EQ-5D to FACT-O, it is difficult to identify the optimal 
mapping algorithm. Instead, a range of plausible mean HSUVs can be derived for 
use in cost-utility analyses.
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objeCtives: To compare indirect utilities for prostate cancer patients obtained 
with a generic (SF-6D) and a disease-specific instrument (Patient Oriented Prostate 
Utility Scale, PORPUS-U). Methods: This was a cross-sectional study of 480 pros-
tate cancer patients enrolled in two similar prospective cohorts. The first one 
included men diagnosed in 2003-2005 with localized prostate cancer (stage T1 
or T2) treated with radical prostatectomy, external radiotherapy, or interstitial 
radiotherapy at 10 hospitals. The second cohort included patients with stage T2 
or T3, treated with external radiotherapy alone or combined with brachytherapy, 
recruited in 2003–2006 at 6 hospitals. Annual computer-assisted telephone inter-
views carried out in both cohorts included several questionnaires: the SF-36v2 
(from which is derived the SF-6D), the PORPUS-U, and the Expanded Prostate 
Cancer Index Composite (EPIC), measuring urinary, bowel, sexual, and hormonal 
domains. ANOVA tests were performed to compare the means of utilities among 
severity groups of severity defined by EPIC items (severe, small or no relevant 
problem). Effect sizes between extreme groups were calculated to estimate the 
magnitude of differences. Results: Mean age was 66.8 years (SD= 6.4) at pros-
tate cancer diagnosis, 20.4% were treated with radical prostatectomy, 33.3% with 
brachytherapy, 26.7% with external radiotherapy, and 19.6% with combined radio-
therapy. The utilities indirectly obtained ranged 0.83-0.99 with PORPUS-U and 
0.61-0.84 with SF-6D. Both instruments showed significant differences according 
to problem severity of all domains measured with EPIC (p< 0.001). Utilities for 
patients without problems were higher than patients with severe problems. The 
effect sizes between the extreme groups with PORPUS-U and SF-6D were: 1.23 and 
1.24 for urinary; 1.03 and 0.75 for bowel; 0.98 and 0.96 for sexual; and 0.94 and 2.17 
for hormonal domains. ConClusions: Our results suggest that both the generic 
index SF-6D and the disease-specific index PORPUS-U discriminated adequately 
the problems related to prostate cancer and their treatments.
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objeCtives: The primary objective of this French prospective multicenter non 
interventional ODISSEE study was to describe daily practice management of 
infra-centimetric Breast Cancer (BC). One secondary objective was to describe 
circumstances of diagnosis and disease announcement. Patients had to answer 
at inclusion a questionnaire regarding satisfaction of the management of their 
disease and upcoming treatment. Methods: From May 2009 to March 2010, 616 
women with infiltrating, unifocal pT1ab, pN0 BC who underwent surgery were 
recruited by 116 centers. Follow-up period is 10 years. Clinical data, treatments 
and outcome were collected in routine visits. Regarding patient’s questionnaire 
at inclusion, seven topics (disease, treatment planned/organization/duration/
side effects, complementary exams needed and disease evolution) were to be 
discussed with their physician at disease discovery and patient’s satisfaction was 
evaluated. Results: 546 (89%) patients answered the questionnaire. All 7 topics 
were discussed with 52% of patients and none of them for 1% of patients. Disease 
and treatment planned was discussed for 98% of patients, for whom 67% were 
fully satisfied and 2% were not satisfied. While 60% of patients aged more than 
50 years old felt fully involved in their treatment choice, only 44% of patients 
aged less than 50 years old felt involved. Overall 12% of patients have considered 
that they have not been involved in their treatment choice. When time between 
disease discovery/physician visit/surgery is short (< 10 days), patient satisfac-
tion is high (> 85%) and when time is greater than 1 month, patient satisfaction 
falls below 40%. Physican specialty (surgeon/oncologist/gyneco-obstetrician) or 
location of disease management (public/private) does not show significant dif-
ference in patient’s satisfaction. ConClusions: 57% of patients felt involved in 
the choice of their treatment, and 65% of patients were globally satisfied of their 
disease management. The shorter is the management of infra-centimetric breast 
cancer, the better is the satisfaction.
values ranged from 0.81–0.90. Pain, severity of disease, urinary and bowel function 
and performance status affected utility values in patients with PC. ConClusions: 
For BC and PC, disease progression, exposure to CT and worsening performance 
status were associated with decreases in utility values. For corresponding disease 
stages, utility values tended to be lower for BC than PC, although heterogeneity of 
data across study populations makes comparisons challenging. No studies reported 
utility values according to response to treatment. Further research is warranted to 
improve the evidence available for CEA.
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objeCtives: The study is designed to capture health related quality of life (HRQL) 
weights for radioiodine refractory differentiated thyroid cancer (RR-DTC) health 
states. Current treatment options for RR-DTC are limited, with generally poor prog-
nosis. As new treatments emerge for RR-DTC, associated cost-effectiveness evalu-
ations require appropriate preference-weighted HRQL values. Methods: Vignette 
descriptions for RR-DTC treatment response and adverse event (AE) health states 
were informed by qualitative work conducted with RR-DTC patients in the US and 
interviews with 6 clinicians and nurses in the UK and US with RR-DTC treatment 
experience. Health states included: stable disease, treatment response, progressive 
disease, stable + grade III diarrhea, stable + grade III fatigue, stable + grade III hand 
foot syndrome (HFS), stable + grade I-II alopecia. The vignettes were reviewed by 
the UK and US clinical experts and piloted with UK general public participants 
in cognitive debrief interviews (n= 5). All vignettes were valued by a UK general 
public sample (n= 100) using a visual analogue scale (VAS) rating and time trade 
off (TTO) interview. Data were analysed using descriptive and regression meth-
ods. Results: The mean TTO health utilities for RR-DTC states ranged from treat-
ment response (0.86; 95% confidence intervals (CI) 0.83,0. 89); through stable disease 
(0.80; CI 0.77, 0.84); to progressive disease (0.50; CI 0.45, 0.56). AEs had a significant 
effect also (stable + grade I-II alopecia (0.75; CI 0.71, 0.79), + grade III fatigue (0.72; 
CI 0.67, 0.77), + grade III HFS (0.52; CI 0.46, 0.58), and + grade III diarrhea (0.42; CI 
0.36-0.48). ConClusions: TTO utilities from this vignette study show clear dif-
ferentiation between RR-DTC states. The order and magnitude of HRQL impact 
demonstrated by the utility values reflected clinical opinion and elicited VAS scores. 
The values reported in this study are suitable for use in cost-effectiveness evalua-
tions for new treatments in RR-DTC.
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objeCtives: Since October 2013, the Haute Autorité de Santé (HAS) requires cost-
effectiveness evidence to assess innovative health technologies. For cost-utility 
assessments, the HAS strongly recommends using French utility values. To date, 
the EQ-5D-3L and the HUI3 are the only instruments with a set of preferences 
values obtained from a representative sample of the French population. In order 
to inform a cost-utility model assessing pharmaceutical treatments of previously-
treated iNHL, this study aimed to review available utility values in France and 
to collect such estimates if necessary. Methods: First, a reproducible MEDLINE 
search was undertaken to identify studies documenting utility values of previously 
treated iNHL and CLL in France. Then, a web-survey including socio-demographic 
and clinical questions as well as the EQ-5D-3L was conducted. Given the difficulty 
to recruit patients from the target population, the questionnaire was conducted 
in France, the United Kingdom, Germany, Italy and Spain. In line with the HAS 
guidelines, French tariffs from Chevalier et al. were applied to the collected EQ-5D 
data. Mean utility values were generated by health state: progression free and 
progressive disease. Results: Only one French cost-utility model conducted by 
Deconinck E. et al was identified as relevant, but the study used English utility 
inputs previously published by Wild et al. Results from the EQ-5D-3L questionnaire 
conducted, illustrated that quality of life was substantially higher in patients with 
stable disease versus patients with progression disease. Utilities were calculated 
with the following scoring function, U (E) = 1–u1-u2-u3-u4-u5–N3. Values between 
u1 to u5 depending of the 3 levels of the 5 dimensions: u1= 0; 0.15; 0.37, u2= 0; 0.21;. 
32; u3= 0; 0.16; 0.19; u4= 0; 0.11;. 026; u5= 0; 0.09; 0.20 and N3= 0.17. ConClusions: 
EQ-5D is a standardised and validated generic instrument which can be used to 
elicit utility in iNHL patients. To our knowledge, these French utilities of previ-
ously-treated iNHL patients are the first to be published.
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objeCtives: Where direct or indirect estimates of health state utility values 
(HSUVs) are not available, mapping algorithms can be used to generate HSUVs 
from health related quality of life data. In a phase II randomised study of olapa-
rib maintenance therapy in platinum-sensitive recurrent ovarian cancer, the 
Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire was 
used. Although no FACT-O mapping algorithms are currently available, several 
algorithms using FACT-General (G) domains of FACT-O have been published. In 
this analysis, we applied FACT-G mapping algorithms to the FACT-O data collected 
in the olaparib study and compared the HSUVs generated. Methods: FACT-O 
data were collected at scheduled visits, and on treatment discontinuation. Three 
